GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD) | MicrobiomeTrials← Back to trialsNCT05303701
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2027-07Est. Completion: 2028-01
Enrollment target: 750 participants Other microbiome trials you might be interested in
Frontotemporal Dementia
This study is testing a new treatment for Frontotemporal Dementia (FTD) - a progressive brain disease that affects perso…
Multiple LocationsEst. completion Oct 31, 2027
Alzheimer Disease (AD)Unwanted LonelinessFamily CaregiversLiving With Process
The absence of social relationships negatively affects physical, psychological, and social health. In other words, it al…
Valencia, SpainEst. completion Dec 2026